InsightsPressBond partners with Luas Diagnostics to add data capture and management to Covid-19 immunity test

Bond partners with Luas Diagnostics to add data capture and management to Covid-19 immunity test

Bond Digital Health has partnered with Luas Diagnostics to add its Transform® data capture and management platform to a new Covid-19 immunity test.

Surrey-based rapid test manufacturer Luas Diagnostics has developed an enhanced test to determine immunity to Covid-19 post infection or vaccination.

The Immunity Test, which is manufactured by Chembio Diagnostics Systems of New York, uses a fingerstick of blood for the detection, differentiation and quantification of IgM and IgG receptor binding domain antibodies to SARS-CoV-2.

The results are read and stored in a portable reader which provides semi-quantitative results in either laboratory or remote settings. The total time to result is 15 minutes.

The Luas Diagnostics app, which is available now in the Google Play store and the Apple App store, is powered by Transform®, Bond Digital Health’s lateral flow data capture platform.

The smartphone app provides a personalised, printable and shareable antibody report and the associated dashboard manages testing, recording and reporting of results in real time at single or multiple locations.

Brendan Farrell, CEO of Luas Diagnostics, said: “We are excited to work together with Bond Digital Health to provide a comprehensive Immunity Test offering with applications in many locations including the workplace, in-store testing, care homes and GP surgeries.

“A recent study has shown that 10-15% of people, particularly among the higher age group, may not produce antibodies even after the second dose of vaccine and thus may have limited protection against the virus. This emphasises the need for individuals to understand their immunity status through regular testing.”

Ian Smith, CEO of Bond Digital Health, said: “Antibody testing is the next tool we should be using in the fight against Covid-19. That’s why we are proud to partner with Luas on their vital Immunity Test.

“But testing alone isn’t enough. Whether in workplaces, care homes, GP surgeries or in the community, we need to capture the test data, store it securely and share it to make sure we have a complete picture of immunity. The Luas App, powered by Transform®, does just that.”

For more details on the Luas test visit:

www.luasdiagnostics.com

About Luas Diagnostics

Luas Diagnostics is based in Guildford, Surrey and is a UK registered private company, which was founded in 2020.

Luas is specialised in the development, manufacture and marketing of rapid tests which can be used Point-of-Care and which are e-health enabled. The focus of our R+D is on the development of rapid, quantitative tests to determine the levels of therapeutic drugs in a patients’ blood using a hand-held reader which transmits the results to a secure cloud for access by physicians.

In addition, we are the exclusive distributor in the UK and Ireland of the Chembio Diagnostic Systems Point-of-care products for infectious diseases

www.luasdiagnostics.com

About Chembio Diagnostic Systems

Chembio Diagnostics Systems of Hauppauge New York is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15-20 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners.

The DPP Covid-19 IgM/IgG test, which is CE marked, uses fingerstick whole blood to produce a result in 15 minutes and separately and simultaneously detects both the IgM and IgG antibodies to Sars-CoV-2, thus providing a result showing whether the patient has been infected and whether it is a current or past infection.

Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Other products in the Chembio portfolio include Point-of-Care tests for HIV (oral fluid and blood), Syphilis, Zika virus and Ebola.

www.chembio.com